Ioannis Gounaris

Company: Merck KGaA

Job title: Head of Clinical Development DDR

Seminars:

ATR: The Target of The Year – How Has this Target Progressed in 2022 & What Are the Current Challenges Faced Clinically 9:30 am

EMD Serono unveiled its new oral ATR inhibitor (M1774) with best-in-class potential The search for BM-defined populations sufficient to support monotherapy registration continues While there have been setbacks for chemotherapy-ATRi combinations, combinations with ICI look increasingly promisingRead more

day: Day One